Skip to main content
    E

    Ensysce Biosciences Inc (ENSC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.42
    +0.03 (+8.06%)

    Market Cap: $8.14M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Ensysce Biosciences Inc (ENSC) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Ensysce Biosciences reported revenue of $5.07M for the fiscal year ended Dec 31, 2025, down 2.8% from the year before. That year, net income was -$10.18M with a net margin of -200.8%, operating cash flow was -$7.81M and free cash flow was -$7.93M. The quarter ended Sep 30, 2026 had revenue of $2.18M and net income of -$82.11M.

    Revenue and Margins

    Over the 6 years to Dec 2025, revenue grew from $1.76M, a compound annual rate of 19.3%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$5.07M-2.8%-104.8%-202.1%-200.8%
    Dec 2024$5.21M+133.5%-38.6%-129.2%-153.3%
    Dec 2023$2.23M-11.6%-240.1%-480.4%-475.7%
    Dec 2022$2.52M-28.5%-686.1%-959.9%-989.2%
    Dec 2021$3.53M-10.2%100.0%-562.7%-825.4%
    Dec 2020$3.93M+122.9%100.0%-41.0%1.4%
    Dec 2019$1.76MN/A-188.7%-188.7%83.7%
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2017 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Revenue$5.07M$5.21M$2.23M$2.52M$3.53M$3.93M$1.76M$0$0
    Cost of revenue$10.38M$7.22M$7.59M$19.84M$151$201$3.33M$1.56MN/A
    Gross profit-$5.31M-$2.01M-$5.36M-$17.31M$3.53M$3.93M-$3.33M-$1.56MN/A
    Research and development$10.38M$7.22M$7.59M$19.84M$4.69M$4.39M$3.40M$0$0
    Operating income-$10.24M-$6.73M-$10.72M-$24.22M-$19.87M-$1.61M-$3.33M-$959.24K-$147.00K
    Net income-$10.18M-$7.99M-$10.61M-$24.96M-$29.15M$56.77K$1.48M$2.12M-$31.19K
    EBITDA-$10.15M-$6.70M-$10.27M-$24.22M-$19.87M-$1.61M-$3.33M-$959.24K-$27.55K
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$2.18M$1.16M$961.00K$1.88M$493.10K$1.37M$1.32M$1.30M$3.42M$181.80K$305.72K$515.03K
    Gross profit-$82.50M$1.16M$954.47K-$1.73M-$2.46M-$551.99K$1.32M-$2.50M$1.73M-$765.43K-$473.00K-$1.72M
    Operating income-$82.50M-$2.58M-$3.56M-$2.78M-$3.74M-$1.75M-$1.97M-$3.58M$644.75K-$1.96M-$1.84M-$3.16M
    Net income-$82.11M-$2.57M-$3.56M-$2.77M-$3.73M-$1.73M-$1.95M-$3.56M$661.77K-$1.97M-$3.12M-$3.50M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $306.71K by $4.00M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$7.45M$5.60M$2.71M$5.89M$16.42M$351.81K$196.51M$204.83M$202.43M
    Current assets$7.24M$5.34M$2.29M$5.30M$15.66M$347.88K$1.20M$1.92M$2.31M
    Cash and equivalents$4.31M$3.50M$1.12M$3.15M$12.26M$194.21K$1.06M$1.66M$2.09M
    Total liabilities$4.57M$2.22M$3.36M$9.91M$24.58M$7.01M$10.34M$7.44M$7.16M
    Short-term debt$306.71K$301.66K$854.70K$4.27M$12.75M$4.27M$2.62M$0$0
    Long-term debtN/AN/AN/A$140.15K$4.44M$791.29K$566.27KN/AN/A
    Shareholder equity$3.21M$3.71M-$322.86K-$4.03M-$8.16M-$6.66M$186.17M$197.39M$195.27M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$30.95M$2.96M$2.17M$7.45M$3.18M$5.57M$4.61M$5.60M$9.38M$2.80M$5.07M$2.71M
    Total liabilities$3.84M$4.07M$2.84M$4.57M$2.30M$2.51M$1.89M$2.22M$2.80M$1.32M$1.65M$3.36M
    Cash and equivalents$29.67M$676.70K$745.48K$4.31M$1.67M$2.21M$3.05M$3.50M$4.15M$1.04M$3.40M$1.12M
    Shareholder equity$27.44M-$781.70K-$340.04K$3.21M$1.20M$3.39M$3.05M$3.71M$6.91M$1.81M$3.75M-$322.86K
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow-$7.81M-$7.50M-$10.78M-$17.89M-$8.24M-$1.25M$10.99M-$1.24M-$251.83K
    Capital expenditures$123.64K$0$2$0$0$0$4$0$0
    Free cash flow-$7.93M-$7.50M-$10.78M-$17.89M-$8.24M-$1.25M$10.99M-$1.24M-$251.83K
    Dividends paidN/A$290.00M$12.94K$913.20K$803.14BN/A$500.00KN/AN/A
    Investing cash flow-$123.64KN/A$0$4.50KN/A$183.40M-$566.29K$838.59K-$200.00M
    Financing cash flow$8.74M$9.88M$8.76M$8.77M$20.31M$1.10M-$11.03M-$32.00K$202.34M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$1.40M-$1.96M-$3.50M-$1.53M-$1.87M-$2.71M-$1.71M-$764.09K-$1.02M-$2.31M-$3.41M-$1.80M
    Capital expenditures$51.75K$0$0$123.64K$123.64K$0$0$0$4$0$3$5
    Free cash flow-$1.45M-$1.96M-$3.50M-$1.65M-$1.99M-$2.71M-$1.71M-$764.09K-$1.02M-$2.31M-$3.41M-$1.80M
    Last 12 quarters

    Frequently Asked Questions About ENSC

    What is Ensysce Biosciences' annual revenue?

    Ensysce Biosciences reported revenue of $5.07M for the fiscal year ended Dec 31, 2025.

    How fast is Ensysce Biosciences' revenue growing?

    Revenue was down 2.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 26.2%.

    Is Ensysce Biosciences profitable?

    No. Ensysce Biosciences reported net income of -$10.18M for the fiscal year ended Dec 31, 2025, with a net margin of -200.8%.

    How much free cash flow does ENSC generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$7.81M minus capital expenditures of $123.64K produced free cash flow of -$7.93M.

    How much debt does Ensysce Biosciences have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $306.71K and cash and equivalents of $4.31M.